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Synovitis in rheumatoid arthritis detected by grey
scale ultrasound predicts the development of
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Abstract
Objectives. To evaluate grey scale US (GSUS) and power Doppler US synovitis (PDUS), separately or in combination
(CombUS), to predict joint damage progression in RA.
Methods. In this cohort study nested in the Swiss RA register, all patients with sequential hand radiographs at their first
US assessment were included. We analysed the summations of semi-quantitative GSUS, PDUS and CombUS assess-
ments of both wrists and 16 finger joints (maximum 54 points) at their upper limit of normal, their 50th, 75th or 87.5th
percentiles for the progression of joint damage (Xray). We adjusted for clinical disease activity measures at baseline, the
use of biological DMARDs and other confounders.
Results. After a median of 35 months, 69 of 250 patients with CombUS (28%), 73 of 259 patients with PDUS (28%) and
75 of 287 patients with available GSUS data (26%) demonstrated joint damage progression. PDUS beyond upper limit of
normal (1/54), GSUS and CombUS each at their 50th (9/54 and 10/54) and their 75th percentiles (14/54 and 15/54) were
significantly associated with Xray in crude and adjusted models. In subgroup analyses, GSUS beyond 14/54 and
CombUS higher than 15/54 remained significantly associated with Xray in patients on biological DMARDs, while clinical
disease activity measures had no significant prognostic power in this subgroup.
Conclusion. Higher levels of GSUS and CombUS are associated with the development of erosions. GSUS appears to
be an essential component of synovitis assessment and an independent predictor of joint damage progression in patients
on biological DMARDs.
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Rheumatology key messages
. The optimal method to demonstrate active synovitis associated with the development of erosions is controversial.
. Synovitis in grey scale was the most robust predictor of erosions in patients with RA.
. Erosion prediction was demonstrated in RA patients with and without biological DMARD therapy.
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Introduction
Major improvements have been achieved in the past dec-
ades in RA outcome, both by the use of novel treatment
options, and by implementation of the ‘treat to target’
strategy aiming at clinical remission [1, 2]. Among the con-
current options, the provisional remission criteria
endorsed by the ACR and the EULAR [3, 4] are the most
stringent ones. However, joint destruction can still occur
in patients whose disease activity appears sufficiently
controlled [5, 6]. In patients treated with TNF inhibiting
(TNFi) and IL-6 receptor inhibiting (IL-6Ri) biological
DMARDs (bDMARDs), an uncoupling between inflamma-
tion and structural damage was noted [612], which may
pose a challenge for the appropriate management of an
increasing number of bDMARD-treated RA patients.
A worse radiographic outcome in RA is more likely in the
presence of synovitis, which may be detected clinically or
by different imaging modalities [13]. Grey scale US
(GSUS), colour Doppler and power Doppler (PDUS) are
capable of detecting clinically verified, as well as subclin-
ical synovitis. Among these US methods, PDUS emerged
as the best predictor of progression of joint damage
[1416]. However, when used as a target for escalating
treatment from conventional to more aggressive anti-
inflammatory therapy, PDUS did not lead to significant
improvement in radiographic outcome in two strategic
treat-to-target trials in early RA [17, 18]. MRI-detected
bone marrow oedema or osteitis was found to be an
even better predictor of joint damage than PDUS in sev-
eral observational studies [9, 15]. Again, when compared
with clinical disease activity, escalation from standard
treatment to bDMARD therapy in response to bone
marrow oedema did not improve the radiographic out-
come in RA patients when starting in clinical remission
or low disease activity [19].
In addition to the predefined very low PDUS treatment
targets in the above-mentioned imaging studies, we set
out to define alternative meaningful US cut-offs from the
Swiss Sonography in Arthritis and Rheumatism (SONAR)
score in comparison with this synovitis level in PDUS as a
predictor of radiographic joint damage progression in a
real-life setting. This study aimed to have a specific
focus on patients treated with bDMARDs. In addition to
re-evaluating PDUS and GSUS separately for another set
of the 28-joint status, we also assessed their combination
(CombUS) as per the most recent recommendation of the
EULAR-OMERACT US Taskforce [20].
Methods
Setting
Data in the Swiss Clinical Quality Management (SCQM)
database [21] were extracted from patients with RA
based on the clinical diagnosis by the treating rheuma-
tologist. Other inclusion criteria were the availability of a
baseline radiograph taken within a time period ranging
from 6 months prior to and up to 3 months after the initial
US assessment of the hands (detailed below) and a
follow-up radiograph taken at least 6 months after the
baseline X-ray. Data collection started on 1 January
2010, and ended on 10 August 2018. All patients gave
their written consent for use of coded data from the
SCQM registry. This study complies with the Declaration
of Helsinki and was approved by Swiss ethics committee
vote KEK-BE 2018-02331.
Outcome and exposure variables
The primary outcome was radiographically detectable
change in joint damage between baseline and follow-up
hand X-rays, expressed in % of the Ratingen score of the
hands [22]. The Ratingen score is a validated semi-quan-
titative method to measure the damaged bone surface by
typical marginal erosions for RA in quintiles [22]. The
range of the Ratingen hands score is 0140. All plain
radiographs are centrally evaluated in SCQM according
to the Ratingen score by a single evaluator without know-
ledge of clinical, sonographic and previous radiographic
data [2325]. The continuous quality management in
SCQM for radiographs of hand and feet reports intraclass
correlation coefficients of minimum 0.98 (0.91; 0.99) for
inter-observer and minimum 0.99 (0.97; 1) for intra-obser-
ver comparisons, with a point estimate of scoring differ-
ence at zero (6; 6) (SCQM internal report, unpublished).
We defined radiographic progression (Xray) as a change
beyond the minimally detectable change of 3.5% (Xray).
The predictor of interest was synovitis detected by dif-
ferent US modalities. PDUS and GSUS was scored ac-
cording to the SONAR score reduced to the hands [26].
This score evaluates synovitis in both wrists, summarizing
the radiocarpal and midcarpal joints into a single joint, and
16 finger joints, which were the second to fifth MCP and
PIP joints. In SONAR, GSUS and PDUS of the wrist scans
were both performed at the dorsal aspect. Finger joints
were scanned for GSUS according to publicly available
reference images at start of US data collection in the
SCQM RA registry from a volar view [27, 28]. Finger
joints were scanned for PDUS at their dorsal aspects
with machine settings as described previously [29].
Joints were scored for GSUS and PDUS from 0 to 3 and
summed separately, or calculated in combination of both
modalities to CombUS according to the EULAR-
OMERACT US Taskforce recommendations [20]. Briefly,
CombUS is zero in the absence of any pathologies in
GSUS and in PDUS. Minimal synovitis (CombUS grade
1) is considered in case GSUS = 1 and by PDUS41.
Moderate synovitis (CombUS grade 2) is defined either
by GSUS = 2 in combination with PDUS42, or by
GSUS = 1 in conjunction with PDUS = 2. Finally, severe
synovitis (CombUS grade 3) is defined by the presence
of GSUS = 3 or PDUS = 3. Thus, each score has a max-
imum of 54. Replaced joints and joints with other con-
straints to performing an appropriate examination in the
standard neutral position were excluded from GSUS and
PDUS analyses. Calculation of any US score required at
least 80% of data completeness. Assuming that synovitis
was similar in unevaluated joints, we performed a linear
extrapolation for up to three joints. In order to perform
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logistic regression analyses for minimal US pathologies,
an external reference for PDUS activity (cut-off 51) was
adopted from ARCTIC [18]. The upper limit of normal 58
in SONAR-GSUS in healthy volunteers [26] served as an
external reference. Additional GSUS, PDUS and CombUS
cut-offs were derived based on the 50th, 75th and 87.5th
percentiles of all scores.
Sonographers in this study were board-certified
rheumatologists with a structured further training in mus-
culoskeletal US (MSUS). All sonographers of this study
had participated in an additional half-day hands-on exer-
cise to train in the scoring method, before the US exam-
inations were locally performed in the participating
centres of SCQM with different commercially available
equipment. One year after training, the kappa value for
inter-reader agreement for the entire process from scan-
ning on different US equipment to scoring was 0.64 for
PDUS and GSUS, which is in the range of published inter-
national data from MSUS experts [30].
Statistics
Results are reported as median and interquartile ranges
for quantitative variables. Data for qualitative variables are
expressed as absolute frequency and as corresponding
percentage. The KruskalWallis test was used for continu-
ous and the Fisher’s exact test for categorical baseline
variables. Radiographic progression was displayed in cu-
mulative probability plots.
Binomial logistic regression with a logit link function was
used to analyse associations between US and the odds
for radiographic progression. We defined a priori a 0.05%
alpha error and obtained post hoc power estimates of
86% for GSUS, 81% for PDUS and 75% for the
CombUS complete dataset model. Age, sex, BMI, an-
aemia according to WHO definition [31], smoking status
(never, former, current), disease duration, RF or anti-CCP
antibody positivity, bDMARD treatment at baseline irre-
spective of its pharmacological target, number of previous
bDMARDs, baseline Ratingen hands score, as well as the
following disease activity measures were alternatively
included each into one of the different adjusted models:
the 28-joint-based clinical disease activity scores
DAS28ESR [32] or DAS28CRP [33], the Simplified Disease
Activity Index or the Clinical Disease Activity Index [34],
DAS28ESR defined low disease activity (43.2) or remission
(<2.6) [35], and Simplified Disease Activity Index or
Boolean method-defined ACR/EULAR-defined remission
[4]. Whenever indicated, missing baseline covariate data
were replaced by multiple imputation using chained equa-
tions with 70 iterations for each dataset. Results from
models from each dataset containing imputed values for
missing covariates were averaged using Rubin’s rule.
Results were defined as consistent in complete baseline
covariate and multiply imputed datasets if (i) the point es-
timate of the covariate of interest with the odds for pro-
gression after multiple imputation using chained equations
was within the CI of the respective estimate in the com-
plete case analysis, and (ii) the inference in both
approaches was consistent in the sense that the P-
values lead to same conclusion.
Subgroup analyses included the following: (i) only ACR/
EULAR 2010 classification criteria-positive patients [36],
(ii) only bDMARD-naı¨ve patients, (iii) only bDMARD-trea-
ted patients since baseline, and (iv) only bDMARD-treated
patients since baseline or starting at any time during ob-
servation. To further characterize the overall diagnostic
performance to predict X-ray progression, we calculated
the sensitivities, specificities and receiver operating curve
characteristics of all the tested US progression risk
categories.
Results
Descriptive statistics
A total of 259 and 287 patients were included into the
PDUS and the GSUS ‘complete case’ analysis, respect-
ively. For the CombUS composite score, 250 patients
were included. Unless explicitly otherwise stated, in the
following we present the CombUS dataset. Descriptive
baseline statistics of this dataset are summarized in
Table 1. The median of all PDUS assessments was 1/54
(Fig. 1). The median in GSUS was 9/54 (Fig. 1). Other rele-
vant cut-off values for later-represented association ana-
lyses were GSUS514/54 at the 75th percentile, CombUS
median 510/54 and CombUS 515/54 at the 75th per-
centile (Fig. 1). Thus, relevant CombUS scores were just
one point higher than the corresponding GSUS scores.
Single adjusted analyses
Median time between baseline and first follow-up X-ray
was 1.4 (interquartile range 1; 2.1) years. Time to progres-
sion in the Ratingen score or last X-ray was 2.9 (1.9; 4.7)
years. Baseline PDUS 51/54, GSUS 59/54, CombUS
510/54, GSUS 514/54 and CombUS 515/54 (Fig. 2)
were each significantly associated with Xray in separate
logistic regression models (Table 2). Point estimates of the
odds ratios (OR) of statistically significant crude associ-
ations were between 1.94 and 2.41. Among the covari-
ates, no clinical disease activity parameter or bDMARD
therapy, but age was significantly associated with Xray
[OR = 1.03 (1.011.05), P = 0.02].
Multivariable adjusted analyses
Multivariable adjusted analyses were performed after im-
putation of missing baseline covariates. As in the crude
analyses, CombUS 515/54 (Table 3), CombUS 510/54,
PDUS 51/54, GSUS 514/54 and GSUS 59/54 (supple-
mentary Tables S1S4, available at Rheumatology online)
were all associated with significantly increased odds for
radiographic progression. The point estimates for the ORs
between Xray and the different US parameters in these
models ranged between 2.3 and 2.9, and were mostly
dependent on US parameters. As in the crude analyses,
no clinical disease activity measure or bDMARD therapy,
but age was significantly associated with radiographic
progression in adjusted models. Notably, the odds for
the different clinical disease activity parameters and
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Xray tended to be stronger in models with less stringent
clinical disease activity parameters. The results after mul-
tiple imputation were consistent with the results in ana-
lyses with complete baseline covariate data.
Subgroup analyses
Subgroup analyses for CombUS (n= 200, 57 events),
PDUS (n= 208, 61 events) and GSUS (n= 227, 61
events) in ACR/EULAR classification criteria-positive pa-
tients [36] confirmed the associations observed in the
entire datasets. For CombUS 510/54 and PDUS 51/54,
we observed a higher OR in ACR/EULAR classifiable
patients than in the total study population (supplementary
Tables S1 and S2, available at Rheumatology online).
Forty-four percent of patients received bDMARDs at
baseline, many of them already as their second or third
bDMARD (Table 1). In the bDMARD-treated patients
at baseline, we detected statistically significant
associations with Xray for CombUS 515/54 [n= 132,
39 events, OR = 4.14 (1.4212.09), P = 0.01] and GSUS
514/54 [n= 153, 45 events, OR 2.82 (1.137), P = 0.03].
No clinical disease activity parameter was significantly
associated with Xray in at baseline bDMARD-treated
patients.
TABLE 1 Description of the study population
CombUS<15/54 CombUS515/54 P-value
Number 185 65
Age (years), median, IQR 54.6, 45.763.5 56.9, 45.867.6 0.30
Female, n 153 53 0.85
Former or currently smoking, n (N) 50 (102) 8 (32) 0.06
Disease duration (years), median, IQR 5.5, 2.212.2 8, 2.616.2 0.20
ACR-EULAR classifiable, n (N) 131 (178) 44 (63) 0.62
Anti-CCP positive, n (N) 145 55 0.37
RF positive, n (N) 131 (184) 43 (65) 0.53
PDUS, median, IQR 1, 02 5, 211 <0.001
GSUS, median, IQR 7, 411 18, 1623 <0.001
BMI, median, IQR (N) 25.6, 22.829.8 (167) 26, 23.529.1(60) 0.92
ACR-EULAR remission, n (N) 25 (68) 2 (21) 0.03
DAS28 CRP, median, IQR (N) 2.6, 1.93.5, (153) 3.5, 2.64.6, (53) <0.001
DAS28 ESR, median, IQR (N) 2.9, 2.33.8, (139) 4, 2.95.2 (52) <0.001
SDAI, median, IQR (N) 7.9, 2.813.4 (66) 9.8, 7.124.1 (21) 0.03
CDAI, median, IQR (N) 6, 211, (74) 11, 624 (23) 0.005
CRP, median, IQR (N) 3, 1.48 (156) 6, 0.516 (55) 0.26
ESR, median, IQR (N) 14, 726 (141) 20, 10.527.5(54) 0.02
SJC28, median, IQR (N) 1, 03 (171) 4, 1.57 (59) <0.001
TJC28, median, IQR (N) 1, 04 (171) 5, 19 (59) <0.001
Ratingen X-ray hands score 6, 213 13, 322 0.0044
HAQ-DI, median, IQR (N) 0.4, 0.10.9 (101) 0.5, 0.11.1 (25) 0.58
Time between US and baseline X-ray (months), median, IQR 0, 04.8 0, 02.9 0.76
Time between baseline and follow-up X-ray (years), median, IQR 1.4, 12 1.5, 1.12.2 0.23
Time between baseline and progression or last
X-ray (years), median, IQR
3, 1.94.7 2.8, 1.94.7 0.99
Calendar year, median, IQR 2012 (20112013) 2011 (20102012) 0.003
On corticosteroid, n 67 28 0.37
On csDMARD, n 113 40 1
On bDMARD, n 85 26 0.47
On TNFi, n 47 14 0.62
On tsDMARD, n 1 0 1
2nd or 3rd line bDMARD, n 52 21 0.41
bDMARD continued, n 38 7 0.13
bDMARD stopped after baseline, n 42 11
bDMARD started after baseline, n 58 27
Time until bDMARD start or switch since baseline
(years), median, IQR (N)
1.32, 0.312.7 (100) 0.5, 0.181.76 (45) 0.04
Presented are baseline data, unless otherwise stated, from patients with complete CombUS hand scores, stratified by
CombUS at its 75th percentile. Continuous data are presented as median and interquartile range (IQR). n: absolute numbers;
N: number with data; bDMARD: biological DMARD; CDAI: Clinical Disease Activity Index: CombUS: combined grey scale and
power Doppler US; csDMARD: conventional synthetic DMARD; DAS28: DAS based on 28 counts; GSUS: grey scale US; HAQ-
DI: HAQ disability index; IQR: interquartile range; PDUS: power Doppler US; SDAI: Simplified Disease Activity Index; SJC:
swollen joint count; TJC: tender joint count; TNFi: TNF inhibitor; tsDMARD: targeted synthetic DMARD.
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Another 35% of patients started bDMARD treatment
during follow-up. Type or duration of treatment at baseline
was not a formal inclusion criterion, but the present study
was performed in an intensively treated RA patient
population. Treatment adaptations were not protocol
guided, but bDMARDs were more often initiated in patients
with clinical and imaging indicators of high disease
activity. Furthermore, bDMARDs were more frequently dis-
continued in subjects with low disease activity indicators.
We illustrate this general finding in Table 1. bDMARDs were
stopped in 23% of patients with CombUS <15/54 vs 17%
of patients with CombUS at baseline 515/54. In contrast,
bDMARDs were started after baseline in 42% of patients
with CombUS 515/54 vs 31% of patients with lower
CombUS scores at baseline. bDMARD therapy indicators
were not significantly associated withXray in crude and in
the multivariable adjusted analyses. This finding was repro-
duced in all the datasets that were obtained after multiple
FIG. 2 Association of synovitis imaging and two alternative clinical disease activity measures with joint damage
progression
Cumulative probability plot of radiographic damage progression (Xray) of the hands are stratified by (A) low
CombUS<15/54 (US) vs high CombUS515/54 (US+), (B) remission or low disease activity in DAS2843.2 (LDAS yes)
vs active disease with DAS28>3.2 (LDAS no) and (C) ACR/EULAR remission present (yes) or absent (no). Probability
plots illustrate the individual mean annual progression in the Ratingen score from baseline to progression or censoring at
the last available radiographs. CombUS: combined grey scale and power Doppler US; LDAS: low disease activity score.
FIG. 1 Distribution of the three tested synovitis US scores over the range
PDUS (left hand panel) is more right shifted than GSUS (middle) and CombUS (right hand panel). Annotated in the PDUS,
GSUS and CombUS score histograms (from left to right) are the cut-off points for 50th, 75th and 87.5th percentiles.
PDUS: power Doppler US; GSUS: grey scale US; CombUS: combined grey scale and power Doppler US.
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imputation using chained equations (Table 3 and supple-
mentary Tables S1S4, available at Rheumatology online).
As before in bDMARD-treated patients at baseline, now in
a larger subgroup of patients who were receiving
bDMARDs at any time, CombUS 515/54 (Table 3) and
GSUS514/54 at baseline (supplementary Table S3, avail-
able at Rheumatology online) was significantly associated
withXray. Furthermore, PDUS51/54 [n= 206, 63 events,
OR 2.15 (95% CI 1.034.47), P = 0.04] (supplementary
Table S2, available at Rheumatology online) and GSUS
59/54 [n= 225, 45 events, OR 1.94 (95% CI 13.76), P =
0.05] (supplementary Table S4, available at Rheumatology
online), but no clinical disease activity measure became
significantly associated with Xray after inclusion of all pa-
tients into analysis with bDMARD therapy since baseline
and those starting later.
Overall diagnostic performance
Despite the many significant associations of US-detected
synovitis and Xray, the formal diagnostic performance of
every single US index test at baseline was not satisfac-
tory. However, as we could not observe a stronger asso-
ciation between Xray and any of the tested clinical
disease activity measures in this study, we consider this
a practically relevant finding. We obtained similar areas
under the curve in the receiver operating characteristics
analyses for PDUS [0.6 (95% CI 0.52; 0.67)], GSUS [0.6
(95% CI 0.53; 0.68)] and CombUS [0.61 (95% CI 0.53;
0.69)]. However, PDUS 51/54 had the best sensitivity
[0.73 (95% CI 0.61; 0.82)], but GSUS 514/54 [0.77
(95% CI 0.71; 0.82)] and CombUS 515/54 [0.78 (95%
CI 0.72; 0.84)] represented the best testing specificities
among the MSUS criteria in significant association with
Xray.
Discussion
This study shows for the first time in a large registry the
value of a single joint US for the risk assessment of radio-
graphic joint damage on a subsequent median 3-year
TABLE 2 Association of US categories and baseline covariates with Xray in single adjusted analyses
Parameter n/N OR 95% CI P-value
GSUS50 59/54 149/286 1.95 1.14, 3.40 0.02
GSUS75 514/54 79/286 2.41 1.37, 4.22 0.002
GSUS87.5 43/286 1.11 0.52, 2.25 0.77
PDUS50 51/54 153/259 2.28 1.28, 4.18 0.006
PDUS75 66/259 1.68 0.92, 3.04 0.09
PDUS87.5 39/259 1.99 0.97, 4.01 0.06
CombUS50 510/54 130/250 1.94 1.11, 3.48 0.02
CombUS75 515/54 65/250 2.2 1.20, 4.02 0.01
CombUS87.5 36/250 1.38 0.63, 2.89 0.41
Sex (female reference) 236/286 0.84 0.40, 1.67 0.64
Age (per year) 286 1.03 1.01, 1.05 0.02
BMI (per unit) 259 0.97 0.92, 1.03 0.33
Anaemia 0/228 0.89 0.38, 1.95 0.79
Current vs never smoker 29/155 2.14 0.90, 5.00 0.08
Former vs never smoker 37/155 0.63 0.17, 1.89 0.44
0.09a
Disease duration (per year) 286 1.02 0.99, 1.04 0.15
Calendar year (per year) 286 0.95 0.80, 1.12 0.55
Anti-CCP positive 195/272 1.08 0.60, 2.00 0.80
RF positive 194/281 1.17 0.66, 2.13 0.60
DAS28 CRP (per unit) 237 1.09 0.87, 1.36 0.44
DAS28 ESR (per unit) 223 1.26 0.47, 1.31 0.57
DAS28 ESR 52.6 vs <2.6 223 1.00 0.53, 1.94 1.0
DAS28 ESR >3.2 vs 43.2 223 1.30 0.71, 2.39 0.40
SDAI (per unit) 89 1.01 0.97, 1.06 0.51
CDAI (per unit) 99 1.01 0.97, 1.05 0.69
Not in ACR/EULAR remission [4] 81/109 1.26 0.47, 3.80 0.66
Baseline Ratingen score 286 1 0.98, 1.01 0.56
No. of prev. bDMARDs (1 vs 0) 39/202 1.6 0.75, 3.32 0.21
No. of prev. bDMARDs (52 vs 0) 46/202 1.4 0.68, 2.81 0.35
258 0.36a
bDMARD at baseline 129/286 1.37 0.80, 2.32 0.25
aP-values for covariates with more than two levels were obtained by likelihood ratio tests. bDMARD: biological DMARD; CDAI:
Clinical Disease Activity Index; CombUS: combined grey scale and power Doppler US; DAS28: DAS based on 28 joint counts;
GSUS: grey scale US; OR: odds ratio; PDUS: power Doppler US; SDAI: Simplified Disease Activity Index; SJC: swollen joint
count; TJC: tender joint count. Subscript 50, 75 and 87.5 denote the 50th, 75th and 87.5th percentiles.
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period. The real life setting of this study with many exam-
iners, long observation time and the different equipment in
use make this result practically relevant. We identified two
candidate cut-off values each in GSUS and CombUS in
association with structural damage progression, one close
to 20% and another at 30% of maximal possible synovitis
pathologies. Furthermore, we found PDUS pathologies at
very low levels similar to that which was used in ARCTIC
[18], and which in The Targeting Synovitis in Early
Rheumatoid Arthritis (TaSER) study [17] were associated
with the development of erosions, but with a lower OR
than the optimal GSUS and CombUS cut-offs. Thus,
quite low grades of synovial pathologies that are not far
from the upper level of normal findings [29] can already be
of relevance for the structural outcome in RA.
The decision about the selection of the joints and the
US technique (volar and dorsal) in the SONAR score to be
evaluated in this study was oriented at the 28-joint status
and available data of US synovitis imaging before 2010
[27, 28]. The US methods remained unchanged in the
Swiss RA cohort over approximately a decade which
made this long-term study possible. However, this metho-
dological stability to the costs of some differences to the
continuously evolving recommendations [20]. Furthermore,
for GSUS and PDUS, SONAR uses the same, universally
applied semi-quantitative scoring system ranging from 03
[20], applied in most US studies, including ARCTIC and
TaSER [17, 18]. Apart from always arbitrary joint selection,
the only major difference between the SONAR and other
GSUS assessments is the exclusive evaluation from the
palmar view. We propose in depth and practically elabo-
rated parameters for further adaptations and testing in
future strategic trials.
The results of the present study have to be interpreted
in the context of more general potential limitations
associated with an observational setting. Patients were
followed-up without a protocol, and there was large vari-
ation in time intervals between follow-up radiographs.
Furthermore, medical treatment was not prescribed per
protocol. Furthermore, with the recommended frequency
of annual visits in the SCQM register, individual changes in
medical treatment could not be tracked back to disease
activity. However, with more treatment intensifications in
case of higher baseline disease activity, the observed
bDMARD treatment adaptations appeared to be in prin-
ciple in accordance with the treat-to-target concept,
which in Switzerland is almost unaffected by restricted
access to drugs. Together with the fact that the vast ma-
jority of patients was at least temporarily exposed to
bDMARDs, this may be a reason that bDMARD treatment
was not per se associated with Xray, although it is evi-
dent from many clinical trials that bDMARDs better inhibit
structural damage progression than conventional syn-
thetic DMARDs. Furthermore, we decided on a linear im-
putation of occasionally missing US data in destroyed or
otherwise unevaluable joints, which may have affected the
precision of the models. As another limitation for adjusted
models, we had to impute the often missing patient global
disease activity parameters necessary to calculate Clinical
Disease Activity Index, Simplified Disease Activity Index
and the ACR-EULAR remission rates. Finally, data could
not be adjusted for unmeasured potentially confounding
genetic data or other information on disease biology [37].
As the SONAR score is hand dominated, we decided a
priori to focus on US as well as radiographic data only of
the hands. This decision limits the generalizability of our
data to other joint regions. Especially the MTP joints are
frequently affected in RA, and their exclusion may be one
of the most important limitations of this study and the
SONAR score in its present form. Furthermore, the
TABLE 3 Association of CombUS75 in combination with different clinical disease activity covariates and Xray
OR for "Xray by CombUS 515/54 Clinical disease activity covariate OR for "Xray by clinical covariate
2.69 (1.285.63), P = 0.0093 DAS28 CRP 1.16 (0.881.53), P = 0.28
2.58 (1.235.54), P = 0.01 DAS28 ESR 1.21 (0.931.57), P = 0.17
2.72 (1.295.74), P = 0.0092 SDAI 1.01 (0.981.05), P = 0.44
2.77 (1.35.89), P = 0.0088 CDAI 1.01 (0.971.05), P = 0.59
2.73 (1.325.64), P = 0.0072 DAS28 ESR >3.2 1.68 (0.853.31), P = 0.14
2.87 (1.385.95), P = 0.0051 DAS28 ESR 52.6 1.19 (0.562.54), P = 0.65
2.85 (1.375.95), P = 0.0055 Not in ACR/EULAR remission 0.83 (0.361.88), P = 0.65
Subgroup analyses
2.7 (1.225.98), P = 0.02a DAS28 ESR >3.2 vs 43.2 1.68 (0.853.31), P = 0.14
4.14 (1.4212.09), P = 0.01b DAS28 ESR >3.2 vs 43.2 0.99 (0.382.57), P = 0.98
2.72 (1.236.02), P = 0.01c DAS28 ESR >3.2 vs 43.2 1.26 (0.612.61), P = 0.53
2.74 (0.858.77), P = 0.09d DAS28 ESR >3.2 vs 43.2 2.75 (0.918.3), P = 0.07
Multiple variable adjusted logistic regression analyses were performed in the complete dataset (n= 250/69 events) and dif-
ferent subgroups after MICE. aDataset of only ACR/EULAR classification criteria-positive patients (n= 200, 57 events).
bPatients treated with bDMARD at baseline (n= 132, 39 events). cbDMARD-treated patients at baseline or started later
during follow-up (n= 197, 59 events). dbDMARD-naı¨ve patients at baseline (n= 118, 30 events). bDMARD: biological
DMARD; CDAI: Clinical Disease Activity Index; DAS28: DAS based on 28 joint counts; CombUS: combined grey scale and
power Doppler US; MICE: multiple imputation in chained equations; OR: odds ratio (margins of 95% CI); SDAI: Simplified
Disease Activity Index. Subscript 75 denotes the 75th percentile.
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applied Ratingen X-ray score has a numerical range of
pathologies for hands that is 20 points lower compared
with the van der Heijde Sharp score, which goes up to 160
points [38]. As far as is comparable when obtained from
different studies, the Ratingen score appears to have 10%
lower standardized response means than the van der
Heijde Sharp score [39, 40]. However, it could be
argued that less sensitivity to change may even
strengthen the results in terms of being able to demon-
strate tangible differences.
This study population contained many bDMARD-trea-
ted patients. It is commonly recognized that the link be-
tween damage progression and clinical disease activity
may be disconnected in patients on this type of therapy
[7, 8, 11, 12]. Taking this into consideration, the finding
that clinical disease activity measures were associated
with structural outcome only in patients without
bDMARD therapy was not unexpected. Furthermore, the
complexity of the models was reduced to only baseline
exposure data, which does not cover fluctuations in dis-
ease activity over time [6, 41, 42]. Nevertheless, we
handled clinical and MSUS data in exactly the same
way. As far as demonstrated, GSUS and CombUS, ob-
tained at only one occasion, was in itself informative for
detecting an increased risk of joint damage progression
over such a long period of time. Regarding other covari-
ates, we observed a statistically significant association of
age with erosive progression. More severe arthritis and
accelerated joint damage progression in elderly RA pa-
tients has been observed previously [43]. In contrast to
some previous studies, joint damage was not associated
with RF or CCP antibody status [44, 45] in this study.
As a consequence of the negative outcome for the ima-
ging arms in ARCTIC, TaSER and Imagine-RA [1719],
arthritis imaging should be restricted to difficult diagnostic
situations [46]. Identification of the progression of erosions
in RA patients on bDMARD therapy appears to have the
most relevance to these challenging situations [7, 8], in
which imaging synovitis according to the present data
appears to make sense. Patients treated with bDMARDs
typically have only small changes in joint damage. Thus,
the significance of the amount in Xray used in this study
might be debatable, but protection of the joint structures
is a central aspect of good long-term outcomes. As
bDMARDs are increasingly used worldwide, our findings
will probably gain even more relevance in the near future.
Though PDUS was on its own a predictor of damage pro-
gression in several studies [1416], inclusion of PDUS into
CombUS here did not provide a major additional benefit.
We have no clear evidence from our own data [30], but we
consider technical and methodological issues in daily
practice to be a more relevant problem for the reliability
and validity of PDUS than for GSUS.
In summary, this large, multicentre, real-life study
strongly suggests the usefulness of imaging synovitis to
predict the structural disease outcome from a perspective
of years, especially in RA patients on bDMARD therapy.
Exceeding 2030% of the maximum synovitis grading in
GSUS or in CombUS appeared to be of equivalent
relevance. This result does not contradict the importance
of synovial hypervascularity or even more of osteitis for
joint destruction, which cannot be displayed by synovitis
US, nor does this study call into question the current pri-
macy of a treat-to-target concept on the basis of reiter-
ated clinical disease activity assessments. While our
observations highlight the importance of synovitis for the
destructive course of RA, ongoing technical and meth-
odological improvements in US imaging synovitis appear
likewise necessary and achievable.
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